top of page
  • matthewwitkowski4

Cancer League of Colorado Research Grant Awarded

Updated: Sep 9, 2022

June 1st, 2022

Recent breakthroughs allow a B-ALL patient's own immune cells to be trained to recognize and kill their leukemia. For example, Chimeric Antigen Receptor (CAR) T cell therapy begins with isolating a cell type known as T cells from a B-ALL patient’s blood. These patient-derived T cells, which normally eliminate cells infected with viruses and bacteria, are engineered in a specialized laboratory to target a protein known as CD19, found on the B-ALL cell surface. CAR-T cells are then infused back into the B-ALL patient's body, where they search for CD19 present on B-ALL cells. Once CD19 is engaged, CAR-T cell destroys their B-ALL cell target.

The amount of CD19 protein present on B-ALL cells is critical for CAR-T cells to find their target. B-ALL cells expressing low surface CD19 levels may fail to be killed by CAR-T cells. To overcome this with the support of the Cancer League of Colorado, we will ask; which genetic pathways limit the amount of CD19 expressed by a B-ALL cell? Furthermore, can we inhibit these pathways and increase B-ALL surface CD19 protein levels, thus, helping CAR-T cell's find their target?

We would like to extend our appreciation to the Cancer League of Colorado for supporting the Witkowski laboratory in this endeavor.


Recent Posts

See All
bottom of page